Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 1997-04-28
- Employees
- 19.6K
- Market Cap
- -
- Website
- http://www.hengrui.com
Merck Licenses Oral Lipoprotein(a) Inhibitor HRS-5346 from Hengrui Pharma in $1.97 Billion Deal
Merck has secured exclusive global rights (excluding Greater China) to HRS-5346, an investigational oral small molecule Lipoprotein(a) inhibitor currently in Phase 2 trials in China.
IDEAYA Biosciences Licenses DLL3-Targeting ADC from Hengrui Pharma in $1B Deal
IDEAYA Biosciences has secured an exclusive license from Hengrui Pharma for SHR-4849, a DLL3-targeting antibody-drug conjugate (ADC), outside of Greater China.
Rivoceranib Plus Camrelizumab Shows Promise in First-Line HCC Treatment
The CARES-310 trial demonstrated that rivoceranib plus camrelizumab significantly improved overall survival in patients with unresectable or metastatic hepatocellular carcinoma (HCC).
FDA Accepts Resubmission of NDA for Rivoceranib and Camrelizumab in Unresectable Hepatocellular Carcinoma
The FDA has accepted the resubmitted NDA for rivoceranib and camrelizumab as a first-line treatment for unresectable or metastatic hepatocellular carcinoma.
Elevar Therapeutics Plans NDA Resubmission for Rivoceranib/Camrelizumab in Unresectable HCC After CRL
Elevar Therapeutics plans to resubmit its NDA for rivoceranib plus camrelizumab to the FDA for treating unresectable hepatocellular carcinoma (HCC).